Cancer Immunotherapy Biomarkers Beyond PD-L1: Emerging Tools for Predicting Treatment Response

 

Cancer Immunotherapy Biomarkers Beyond PD-L1: Emerging Tools for Predicting Treatment Response

Cancer immunotherapy has transformed the way many cancers are treated by harnessing the body's own immune system to recognize, attack, and eliminate malignant cells. Immune checkpoint inhibitors, cellular therapies, and other immunotherapeutic approaches have produced long-lasting responses in patients with several advanced and difficult-to-treat cancers. However, despite these remarkable advances, immunotherapy does not work equally well for every patient. Some individuals experience substantial and durable tumor regression, while others show little or no response, and some patients initially respond before their tumors eventually become resistant.

This variation in treatment response has made biomarker discovery one of the most important areas of modern cancer research. Biomarkers can provide valuable information about tumor biology, immune activity, treatment sensitivity, and mechanisms that may influence therapeutic outcomes. Among the biomarkers currently used in clinical oncology, programmed death-ligand 1 (PD-L1) expression has played an important role in guiding the use of immune checkpoint inhibitors. However, PD-L1 alone does not completely explain the complex relationship between a tumor and the patient's immune system.

Patients with high PD-L1 expression may sometimes fail to respond to immunotherapy, while patients with low or undetectable PD-L1 expression can occasionally achieve meaningful clinical benefits. Differences in tumor genetics, immune-cell infiltration, tumor microenvironment, antigen presentation, immune signaling, and treatment history can all influence therapeutic response. These limitations have encouraged researchers to look beyond PD-L1 and investigate a broader range of emerging immune biomarkers.

The next generation of precision immuno-oncology is therefore moving toward a multidimensional approach in which several biological characteristics are evaluated together rather than relying on a single marker. Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), mismatch repair deficiency, neoantigen production, interferon-gamma signaling, CD8+ T-cell infiltration, immune gene-expression profiles, and emerging immune checkpoint molecules are among the areas being extensively investigated.

At the same time, advances in molecular diagnostics are creating new opportunities to identify biomarkers from blood, tumor tissue, and other biological samples. Circulating tumor DNA (ctDNA), extracellular vesicles and exosomes, circulating immune cells, and other liquid biopsy components are being explored for their potential to provide real-time information about tumor evolution and treatment response. These approaches may eventually allow researchers and clinicians to detect changes in cancer biology earlier than conventional imaging or tissue-based testing.

Another important development is the growing recognition that the tumor microenvironment plays a central role in determining whether immunotherapy succeeds or fails. Cancer cells do not exist in isolation. They interact with T cells, B cells, macrophages, dendritic cells, fibroblasts, endothelial cells, cytokines, chemokines, and extracellular components that collectively influence immune activity within the tumor. A tumor that appears immunologically active may respond very differently from one characterized by immune exclusion or immune suppression, even when both tumors express similar levels of PD-L1.

Emerging biomarkers are increasingly being studied to capture these complex interactions. The density and location of CD8+ T cells, the activity of immune-related gene signatures, the presence of suppressive myeloid populations, stromal characteristics, and the expression of alternative immune checkpoints such as LAG-3 and TIGIT may provide additional information about the immune state of a tumor. These markers could help researchers understand why some tumors remain sensitive to immune-based treatment while others develop primary or acquired resistance.

Genomic characteristics are also becoming increasingly important in immunotherapy research. Tumors with specific genetic alterations can generate abnormal proteins, or neoantigens, that may be recognized by the immune system. Similarly, tumors with high mutational burden or defects in DNA repair pathways may possess biological features that influence immune recognition. Understanding these relationships can help researchers identify patient populations that are more likely to benefit from particular immunotherapeutic approaches.

However, no single biomarker is expected to provide a universal solution for predicting immunotherapy response. Cancer is highly heterogeneous, and its biological characteristics can change over time. A biomarker measured before treatment may not accurately represent the tumor after several treatment cycles. Cancer cells can evolve, immune-cell populations can change, and the tumor microenvironment can become increasingly suppressive. Therefore, dynamic biomarkers and longitudinal monitoring are becoming increasingly important areas of investigation.

Technological advances are helping researchers address these challenges. Artificial intelligence, machine learning, digital pathology, spatial analysis, single-cell technologies, transcriptomics, proteomics, and multi-omics approaches are enabling scientists to examine cancer and immune responses at increasingly detailed levels. Instead of evaluating one characteristic at a time, researchers can integrate multiple layers of biological information to identify patterns associated with treatment sensitivity or resistance.

Digital pathology, for example, can help researchers quantify immune-cell distribution and examine spatial relationships between tumor cells and immune populations within tissue. Single-cell technologies can reveal differences between individual immune and tumor-cell populations that may be hidden in conventional bulk analysis. Multi-omics approaches can combine genomic, transcriptomic, proteomic, and other molecular information to provide a more comprehensive picture of the tumor-immune ecosystem.

The development of better biomarkers could have significant implications for personalized cancer treatment. More accurate patient stratification could help clinicians select appropriate immunotherapies, identify patients who may benefit from combination approaches, and reduce exposure to treatments that are unlikely to provide meaningful benefit. Biomarkers may also support treatment monitoring by helping identify early signs of response, disease progression, or emerging resistance.

Importantly, the future of immunotherapy biomarker research is not simply about finding a replacement for PD-L1. Instead, it is about developing a more comprehensive understanding of why immunotherapy works, why it fails, and how treatment can be adapted to the biological characteristics of each patient's cancer. This shift represents an important step toward a more precise and dynamic model of cancer care.

As research continues, combinations of tissue-based biomarkers, blood-based biomarkers, genomic information, immune profiles, and computational analysis may provide more reliable predictions than any individual marker. Such integrated strategies could ultimately support real-time treatment decisions and help move precision oncology from static tumor classification toward continuously personalized cancer management.

The growing field of immunotherapy biomarker research beyond PD-L1 therefore represents an important frontier in oncology. By combining advances in molecular biology, immunology, pathology, genomics, liquid biopsy, artificial intelligence, and precision medicine, researchers are working toward a future in which cancer treatment can be selected and adjusted according to the unique biological characteristics of each tumor.

This evolving approach could help overcome some of the major limitations of current immunotherapy strategies and contribute to more effective, durable, and personalized cancer treatment. As new biomarkers move from laboratory research toward clinical validation, their ability to predict treatment response, monitor disease evolution, and guide therapeutic decisions will remain a major focus of cancer research in the years ahead.

Understanding Immunotherapy Biomarkers Beyond PD-L1

The development of cancer immunotherapy has created a major need for reliable biomarkers that can help predict which patients are most likely to benefit from treatment. Although PD-L1 remains an important clinical biomarker, its predictive value varies across cancer types and treatment settings. Researchers are therefore investigating multiple biological characteristics that may provide a more complete picture of tumor–immune interactions.

1. Why PD-L1 Alone Is Not Enough

PD-L1 expression is commonly evaluated to determine whether a tumor may be more likely to respond to certain immune checkpoint inhibitors. However, PD-L1 expression can vary between different areas of the same tumor and can also change during disease progression or treatment.

A tumor may have high PD-L1 expression but still avoid immune attack through other mechanisms. Conversely, some patients with low PD-L1 expression can experience meaningful responses to immunotherapy.

These limitations demonstrate that immunotherapy response is controlled by multiple biological factors rather than a single molecular marker. This has encouraged researchers to investigate complementary biomarkers that can capture tumor genetics, immune-cell activity, and the characteristics of the tumor microenvironment.

2. Tumor Mutational Burden and Immune Response

Tumor Mutational Burden (TMB) measures the number of mutations present within a tumor's genome. A higher number of mutations may increase the possibility of generating abnormal proteins that can be recognized by the immune system.

Because of this relationship, TMB has been investigated as a potential biomarker for predicting response to immune checkpoint inhibitors. However, TMB is not a universal predictor of treatment benefit. Its interpretation can be influenced by cancer type, sequencing methods, mutation thresholds, and other biological characteristics.

This highlights an important principle in precision oncology: biomarkers should be interpreted within the broader biological context of an individual tumor.

3. Microsatellite Instability and Mismatch Repair Deficiency

Microsatellite instability (MSI) and mismatch repair deficiency (dMMR) represent another important group of biomarkers associated with immunotherapy response.

When DNA mismatch repair mechanisms are impaired, cancer cells can accumulate genetic changes. These alterations may increase the production of abnormal proteins that make tumor cells more visible to the immune system.

The identification of MSI-high and dMMR tumors has therefore become an important component of precision cancer treatment. Testing for these characteristics can help identify certain patients who may benefit from immune checkpoint blockade.

4. Neoantigens as Emerging Biomarkers

Neoantigens are abnormal proteins or protein fragments that arise from tumor-specific genetic alterations. Because these molecules are not normally present in healthy cells, they may be recognized by the immune system as foreign.

Researchers are investigating neoantigen quantity, quality, and immune recognition as potential indicators of immunotherapy sensitivity. Advances in sequencing and computational prediction are making it increasingly possible to identify candidate neoantigens within individual tumors.

Neoantigen research is also closely connected with personalized cancer vaccines and other immune-based treatment strategies. In the future, neoantigen profiles could potentially contribute to highly individualized immunotherapy approaches.

5. CD8+ T-Cell Infiltration

The presence and activity of immune cells inside a tumor can provide important information about the likelihood of an immune response.

CD8+ T cells are particularly important because they can recognize and destroy cancer cells. Tumors containing substantial numbers of active cytotoxic T cells are sometimes described as having an immune-infiltrated or "hot" tumor environment.

However, simply measuring the number of T cells may not be sufficient. Researchers are increasingly examining their location, functional state, activation status, and interaction with cancer cells.

Understanding these characteristics may provide more meaningful information about whether immune cells are capable of mounting an effective antitumor response.

6. Immune Gene-Expression Signatures

Gene-expression profiling provides another approach for studying immunotherapy response. Instead of focusing on one protein or mutation, researchers can analyze groups of genes associated with immune activation, inflammation, interferon signaling, T-cell activity, and other biological processes.

These gene-expression signatures may help identify tumors with active immune responses and distinguish them from tumors with immune-excluded or immune-suppressed environments.

As computational technologies improve, researchers are increasingly investigating whether combinations of gene-expression patterns can provide more reliable predictions than individual biomarkers.

7. The Tumor Microenvironment as a Biomarker Source

The tumor microenvironment contains numerous cell types and molecular signals that influence cancer progression and treatment response.

Immune-suppressive macrophages, regulatory T cells, cancer-associated fibroblasts, cytokines, chemokines, and extracellular matrix components can create conditions that restrict immune-cell activity.

Consequently, researchers are investigating the tumor microenvironment itself as a source of predictive biomarkers. Spatial information is particularly important because the location of immune cells relative to cancer cells may influence treatment response.

New technologies such as multiplex imaging and spatial profiling are helping researchers understand these interactions with increasing precision.

8. Emerging Immune Checkpoint Biomarkers

PD-1, PD-L1, and CTLA-4 are among the best-known immune checkpoint pathways, but they are not the only mechanisms controlling immune responses.

Other immune checkpoints, including LAG-3, TIGIT, TIM-3, and related pathways, are being investigated as potential therapeutic targets and biomarkers.

Understanding the expression and activity of these pathways could help identify patients who may benefit from next-generation immunotherapies or combination checkpoint strategies.

This area of research is particularly important for patients whose tumors do not respond adequately to conventional checkpoint inhibition.

9. Liquid Biopsy and Dynamic Biomarkers

Traditional biomarker testing often depends on a tissue sample collected at a specific point in time. However, cancer biology can change continuously during treatment.

Liquid biopsy technologies offer an opportunity to monitor tumor-associated molecular signals through blood samples. Circulating tumor DNA (ctDNA) is one of the most extensively investigated approaches for tracking tumor dynamics.

Changes in ctDNA levels may provide information about treatment response, residual disease, or emerging resistance. Researchers are also studying circulating immune cells, extracellular vesicles, and other blood-based signals as potential immunotherapy biomarkers.

The ability to repeatedly monitor biomarkers could eventually support more dynamic treatment decisions.

10. Artificial Intelligence in Biomarker Discovery

The growing volume of genomic, imaging, pathology, and molecular data has created opportunities for artificial intelligence and machine learning in biomarker research.

AI systems can analyze complex datasets to identify patterns that may not be easily recognized through conventional approaches. Digital pathology platforms, for example, can evaluate tumor architecture, immune-cell distribution, and spatial relationships within tissue.

When combined with genomic and clinical information, computational approaches may help researchers discover new biomarker combinations capable of predicting immunotherapy response more accurately.

11. Multi-Omics for Comprehensive Immunotherapy Prediction

One of the most promising directions in precision immuno-oncology is multi-omics integration.

Genomics can reveal mutations and genomic alterations, transcriptomics can show gene activity, proteomics can provide information about protein expression, and other molecular technologies can reveal additional layers of tumor biology.

Integrating these datasets may allow researchers to develop more comprehensive models of the tumor–immune ecosystem.

Rather than asking whether one biomarker is positive or negative, future approaches may evaluate multiple biological dimensions simultaneously to generate a more individualized prediction of treatment response.

12. Biomarkers for Monitoring Treatment Response

Biomarkers are not only important before treatment begins. They may also help researchers understand what happens after therapy starts.

A patient may initially respond to immunotherapy and later develop progressive disease. Monitoring molecular changes over time could help identify emerging resistance before it becomes clinically obvious.

Dynamic biomarker analysis may therefore become increasingly important for adapting treatment strategies, selecting combination therapies, and determining whether a therapy should be continued or modified.

13. Challenges in Developing Reliable Immunotherapy Biomarkers

Despite significant progress, several challenges remain.

Biomarker measurements can differ between laboratories and testing platforms. Tumor heterogeneity can produce different results from different areas of the same cancer. Biomarker levels may also change during treatment.

Furthermore, a biomarker that performs well in one cancer type may not have the same predictive value in another.

For these reasons, researchers need robust clinical validation, standardized testing methods, large patient cohorts, and carefully designed clinical trials before emerging biomarkers can become widely adopted.

14. The Future of Immunotherapy Biomarker Research

The future is likely to move away from relying on a single biomarker and toward integrated biomarker models.

A combination of PD-L1 status, genomic alterations, TMB, MSI, immune-cell characteristics, gene-expression signatures, tumor microenvironment features, liquid biopsy data, and clinical factors could provide a more complete representation of treatment sensitivity.

Advances in AI and multi-omics analysis may further improve these predictive models by identifying complex interactions between cancer cells and the immune system.

Ultimately, the goal is to make immunotherapy more precise: identifying the right patient, selecting the most appropriate treatment, monitoring the response continuously, and adapting therapy as the tumor evolves.

Conclusion

The evolution of cancer immunotherapy has demonstrated that treatment response is influenced by a complex interaction between tumor biology and the immune system. While PD-L1 remains an important biomarker in clinical practice, its limitations have made it increasingly clear that a single biomarker cannot fully predict how an individual patient will respond to immunotherapy.

Emerging biomarkers such as Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), mismatch repair deficiency, neoantigens, immune-cell infiltration, immune gene-expression signatures, and alternative immune checkpoints are providing researchers with deeper insights into the mechanisms that influence immunotherapy effectiveness. At the same time, liquid biopsy, circulating biomarkers, digital pathology, spatial technologies, and advanced molecular profiling are creating new possibilities for monitoring cancer and immune responses over time.

The integration of these diverse biomarkers with artificial intelligence, multi-omics analysis, and precision oncology could significantly improve the ability to identify patients who are most likely to benefit from specific immunotherapeutic strategies. Rather than depending on one measurement, future treatment decisions may increasingly rely on comprehensive molecular and immune profiles that reflect the unique characteristics of each patient's tumor.

Continued research and clinical validation will be essential to determine which emerging biomarkers can reliably guide treatment decisions across different cancer types. As our understanding of tumor–immune interactions continues to expand, biomarker-driven immunotherapy may help overcome some of the current limitations of cancer treatment and support more personalized therapeutic approaches.

The future of immuno-oncology is therefore moving beyond simply asking whether a patient is PD-L1 positive or negative. The larger goal is to understand the complete biological landscape of the tumor, predict its response to treatment, monitor changes during therapy, and adapt treatment strategies accordingly.

With rapid advances in molecular diagnostics, computational biology, immunology, and precision medicine, cancer immunotherapy biomarkers beyond PD-L1 represent an important frontier in modern oncology research. These developments could contribute to more informed treatment selection, improved response prediction, and ultimately more effective and individualized cancer care.

Join Oncology Summit-2027

The International Experts Summit on Oncology & Cancer Care (Oncology Summit-2027) will bring together international oncologists, cancer researchers, clinicians, healthcare professionals, scientists, academics, and industry experts to discuss emerging developments in oncology and cancer care.

📅 March 25–27, 2027
📍 Osaka, Japan
📧 Email: OncologySummit-2027@iconicmeetings.biz

The summit will provide an international platform for sharing research, presenting innovative findings, exploring emerging cancer therapies, and building scientific collaborations across the oncology community.

Researchers, clinicians, healthcare professionals, and oncology experts are invited to participate in Oncology Summit-2027 and contribute to discussions shaping the future of precision cancer care and immuno-oncology.

Frequently Asked Questions (FAQs)

1. What are cancer immunotherapy biomarkers?
Cancer immunotherapy biomarkers are measurable biological characteristics that can provide information about how likely a tumor is to respond to immune-based cancer treatment.

2. Is PD-L1 the only biomarker used for immunotherapy?
No. Although PD-L1 is an important biomarker, researchers are also studying TMB, MSI, mismatch repair status, neoantigens, immune-cell infiltration, gene-expression signatures, and other molecular and immune characteristics.

3. Why is PD-L1 not always an accurate predictor of immunotherapy response?
PD-L1 expression can vary within tumors and may change over time. Some PD-L1-positive tumors do not respond to immunotherapy, while some patients with low PD-L1 expression can still benefit from treatment.

4. What is Tumor Mutational Burden (TMB)?
TMB refers to the number of mutations present in a tumor's genome. It is being investigated as a biomarker because certain mutations can result in abnormal proteins that may be recognized by the immune system.

5. How can MSI and mismatch repair deficiency influence immunotherapy?
MSI and mismatch repair deficiency can lead to the accumulation of genetic alterations in cancer cells. These characteristics can be associated with increased immune recognition and may help identify patients who could benefit from certain immunotherapies.

6. What role do neoantigens play in cancer immunotherapy?
Neoantigens are tumor-specific abnormal proteins that can potentially be recognized by the immune system. Researchers are studying neoantigens as biomarkers and as potential targets for personalized cancer vaccines and other immunotherapy approaches.

7. Can blood-based biomarkers predict immunotherapy response?
Researchers are investigating blood-based biomarkers such as circulating tumor DNA, circulating immune cells, and extracellular vesicles. These approaches may provide opportunities to monitor tumor biology and treatment response over time.

8. How does the tumor microenvironment affect immunotherapy?
The tumor microenvironment contains cancer cells, immune cells, fibroblasts, signaling molecules, and other components that can either support or suppress immune activity. Its characteristics may influence how effectively immunotherapy works.

9. Can artificial intelligence improve immunotherapy biomarker research?
Yes. AI and machine learning can analyze large amounts of genomic, pathology, imaging, and clinical data to identify complex patterns that may help researchers discover and evaluate potential biomarkers.

10. What is the future of immunotherapy biomarker research?
Future research is increasingly focused on combining multiple biomarkers and integrating genomic, immune, pathological, and clinical information to develop more accurate and personalized approaches for predicting and monitoring immunotherapy response.